How a mutated gene receptor and stem cell technology could lead to a cure for HIV

One of Desert Angels’ prominent portfolio companies, Calimmune, has announced it is about to move on to the second half of its Phase 1 human trial, and will soon implant four new patients with its genetically modified stem cells.

Click here for full article